Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2015 07:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Issues Letter to Shareholders

NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and...
September 24, 2014 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Issues Letter to Shareholders

NEW YORK, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
August 13, 2014 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Issues Letter to Shareholders

NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
July 31, 2014 08:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Issues Letter to Shareholders

NEW YORK, July 31, 2014 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
November 14, 2013 14:15 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates

NEW YORK, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and...
July 30, 2013 11:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Retains Chain Pharmaceuticals LLC

NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its...
June 20, 2013 09:25 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Issues Letter to Shareholders

NEW YORK, June 20, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
June 18, 2013 11:31 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Engages Evli Corporate Finance to Explore Strategic Alternatives to Maximize Shareholder Value

NEW YORK, June 18, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
March 29, 2013 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Letter to Shareholders

NEW YORK, March 29, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
February 28, 2013 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona

NEW YORK, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13,...